Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis

Canadian Journal of Gastroenterology

Volumn 18, Issue 6, 2004, Pages 397-399

  Liu, Louis L W C ^a,b   Tarnopolsky, Mark ^a   Armstrong, David ^a  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Botulinum toxin A; Dysphagia; Inclusion body myositis

Indexed keywords

BOTULINUM TOXIN A; DIAZEPAM; PETHIDINE;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; CLINICAL ARTICLE; COUGHING; CRICOPHARYNGEUS MUSCLE; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; DISEASE COURSE; DUODENOSCOPE; DYSPHAGIA; ESOPHAGUS PRESSURE; GENERAL ANESTHESIA; HUMAN; HUMAN TISSUE; INCLUSION BODY MYOSITIS; MALE; MEDICAL DOCUMENTATION; MUSCLE ATROPHY; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOTOMY; PAIN; PRIORITY JOURNAL; SEDATION; THROAT DISEASE; UPPER ESOPHAGUS SPHINCTER;

EID: 4043063616     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/360537     Document Type: Article

References (16)

1. Tawil R, Griggs RC. Inclusion body myositis. Curr Opin Rheumatol 2002;14:653-7.
2. Houser SM, Calabrese LH, Strome M. Dysphagia in patients with inclusion body myositis. Laryngoscope 1998;108:1001-5.
3. Ross ER, Green R, Auslander MO, Biller HE Cricopharyngeal myotomy: Management of cervical dysphagia. Otolaryngol Head Neck Surg 1982;90:434-41.
4. Danon MJ, Friedman M. Inclusion body myositis associated with progressive dysphagia: Treatment with cricopharyngeal myotomy. Can J Neurol Sci 1989; 16:436-8.
5. Darrow DH, Hoffman HT, Barnes GJ, Wiley CA. Management of dysphagia in inclusion body myositis. Arch Otolaryngol Head Neck Surg 1992;118:313-7.
6. Riminton DS, Chambers ST, Parkin PJ, Pollock M, Donaldson IM. Inclusion body myositis presenting solely as dysphagia. Neurology 1993;43:1241-3.
7. Verma A, Bradley WG, Adesina AM, Sofferman R, Pendlebury WW. Inclusion body myositis with cricopharyngeus muscle involvement and severe dysphagia. Muscle Nerve 1991;14:470-3.
8. Wintzen AR, Bots GT, de Bakker HM, Hulshof JH, Padberg GW Dysphagia in inclusion body myositis. J Neurol Neurosurg Psychiatry 1988;51:1542-5.
9. Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kalloo AN. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med 1995;332:774-8.
10. Schneider I, Thumfart WF, Pototschnig C, Eckel HE. Treatment of dysfunction of the cricopharyngeal muscle with botulinum A toxin: Introduction of a new, noninvasive method. Ann Otol Rhinol Laryngol 1994;103:31-5.
11. Shaw GY, Searl JP. Botulinum toxin treatment for cricopharyngeal dysfunction. Dysphagia 2001;16:161-7.
12. Haapaniemi JJ, Laurikainen EA, Pulkkinen J, Marttila RJ. Botulinum toxin in the treatment of cricopharyngeal dysphagia. Dysphagia 2001;16:171-5.
13. Cherin P, Pelletier S, Teixeira A, et al. Intravenous immunoglobulin for dysphagia of inclusion body myositis. Neurology 2002;58:326.
14. Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: A double-blind, placebo-controlled study. Neurology 1997;48:712-6.
15. Kaplan S. Paralysis of deglutition, a post-poliomyelitis complication treated by section of the circopharyngeus muscle. Ann Surg 1951;133:572-3.
16. Kelly JH. Management of upper esophageal sphincter disorders: Indications and complications of myotomy. Am J Med 2000;108(Suppl 4A):43S-6S.